MVA vaccine for delivery of a UL128 complex and preventing CMV infection
AssigneeCity of Hope
InventorsDon J. Diamond, Felix Wussow
Life of this patent
Estimating the term…
Loading patent…
AssigneeCity of Hope
InventorsDon J. Diamond, Felix Wussow
Estimating the term…
In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.
An expression system comprising a bacterial artificial chromosome (BAC) construct, the BAC construct comprising a modified vaccinia Ankara (MVA) viral vector inserted with DNA sequences that encode cytomegalovirus (CMV) UL128, UL130, UL131A, glycoprotein L (gL), and glycoprotein H (gH) proteins or antigenic fragments thereof,
A vaccine for inhibiting CMV infection comprising:
Dependencies are inferred from the claim text.